News for hackers. Stuff that matters.

A comment on Survival of HIV+ patients starting antiretroviral therapy between 1996 and 2013. Parent comment

Re:Survival of HIV+ patients starting antiretroviral therapy... by joewrong on Thursday May 11, 2017 @03:15PM (#14318710)
> CSDD’s finding, a bellwether figure in the drug industry, is based on an average out-of-pocket cost of $1.4 billion and an estimate of $1.2 billion in returns that investors forego on that money during the 10-plus years a drug candidate spends in development.

the estimate includes money that investors could have made if they invested elsewhere?

[ Parent | on HN ]
Re:Survival of HIV+ patients starting antiretroviral therapy... by aantix on Thursday May 11, 2017 @03:29PM (#14318784)
Opportunity costs are real. Promising hypotheses are abundant and cheap. Exploring each with grueling, resource-intense, high-standard science is expensive.

You have to make hard choices.

[ Parent | on HN ]